With 0.14 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.13 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.4299 whereas the lowest price it dropped to was $2.21. The 52-week range on ENTX shows that it touched its highest point at $3.35 and its lowest point at $0.68 during that stretch. It currently has a 1-year price target of $10.00. Beta for the stock currently stands at 1.53.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ENTX was down-trending over the past week, with a drop of -4.49%, but this was up by 7.83% over a month. Three-month performance surged to 27.87% while six-month performance rose 25.13%. The stock gained 120.75% in the past year, while it has gained 10.38% so far this year. A look at the trailing 12-month EPS for ENTX yields -0.26 with Next year EPS estimates of -0.55. For the next quarter, that number is -0.08. This implies an EPS growth rate of 9.68% for this year and -96.43% for next year.
Float and Shares Shorts:
At present, 36.51 million ENTX shares are outstanding with a float of 29.74 million shares on hand for trading. On 2024-12-31, short shares totaled 47328.0, which was 13.0 higher than short shares on 1732838400. In addition to Ms. Miranda J. Toledano M.B.A. as the firm’s CEO & Director, Ms. Dana Yaacov-Garbeli CPA serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.26274002 of ENTX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, ENTX reported revenue of $42000.0 and operating income of -$3021000.0. The EBITDA in the recently reported quarter was -$3010000.0 and diluted EPS was -$0.08.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With ENTX analysts setting a high price target of 10.0 and a low target of 10.0, the average target price over the next 12 months is 10.0. Based on these targets, ENTX could surge 327.35% to reach the target high and rise by 327.35% to reach the target low. Reaching the average price target will result in a growth of 327.35% from current levels.
Analysts have provided yearly estimates in a range of -$0.28 being high and -$0.28 being low. For ENTX, this leads to a yearly average estimate of -$0.28. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
